Modulus in XLIF Study

NuVasive36 enrolled

Overview

The primary objective of this study is to evaluate the safety and performance of the Modulus 3D-printed titanium interbody implant in patients undergoing thoracic and/or lumbar XLIF as measured by reported complications, radiographic outcomes, and patient-reported outcomes.

Patients considered for this study will have previously undergone surgery for their spinal condition according to the standard of care of the practitioner. All patients at a given site who meet eligibility requirements will be asked to consent to participate in the study. Once enrolled in the study, subjects will undergo a computed tomography (CT) scan at 12 months postoperative or later to evaluate their fusion status. If the patient already had a postoperative CT scan at 12 months or greater, this will be used in this study and an additional CT scan should not be performed for this study. Available progress notes, medical records, patient-reported outcomes, radiographs (plain film and CT scans, if available), and complications will be obtained from the medical records of all enrolled subjects. The safety and performance of the Modulus XLIF interbody implant will be assessed using the following: 1. Complications attributable to the use of the Modulus XLIF interbody implant as noted in surgical summaries, progress notes, and hospital records 2. Radiographic outcome (fusion) and description of device status from plain film radiographs and CT scan(s) 3. Neurologic status, symptoms, and/or subject self-reported clinical outcomes (e.g., pain and disability), as available

Study Type

OBSERVATIONAL

Enrollment

Conditions

Degenerative Disc Disease Degenerative Spondylolisthesis Degenerative Scoliosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female patients who are ≥18 years of age at the time of surgery 2. Treated with XLIF procedure with the Modulus 3D-printed titanium interbody implant at: 1. One or two thoracic and/or lumbar levels for degenerative disc disease or degenerative spondylolisthesis, or 2. Any number of thoracic and/or lumbar levels for degenerative scoliosis (defined as \>10º coronal curve) 3. Interbody fusion with autograft and/or allograft 4. Any NuVasive supplemental fixation 5. Patient is able and to undergo a CT scan. If the patient already had a postoperative CT scan at 12 months or greater, this will be used in this study and an additional CT scan should not be performed for this study. 6. Patient understands the conditions of enrollment and is willing to sign an informed consent form to participate. Exclusion Criteria: 1. Use of any bone graft with the Modulus XLIF interbody implant that is not FDA-cleared for use in the interbody space. Examples of these include: 1. Bone morphogenetic protein (BMP) (e.g., Infuse (Medtronic)) 2. Synthetic bone graft extenders (e.g., AttraX (NuVasive), Formagraft (NuVasive), Mastergraft (Medtronic), Vitoss (Stryker), Actifuse (Baxter), nanOss (RTI Surgical), Fibergraft (Prosidyan/Depuy Synthes), ChronOs (Depuy Synthes)) 3. Demineralized bone matrices (DBM) regulated as medical devices by the FDA (e.g., Grafton Putty/Gel (Medtronic), DBX (MTF/Depuy Synthes), Accell Evo3 (IsoTis), Propel Putty/Gel (NuVasive)) 4. Peptide enhanced bone graft (e.g., iFactor (Cerapedics)) 2. Previous lumbar fusion surgery at the currently treated level(s) (adjacent-level surgery is acceptable) 3. Patients with active infection at the surgical site at the time of surgery 4. Patient is involved in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested) 5. Patient is unwilling or unable to undergo a CT scan due to pregnancy or other medical condition 6. Patient is a prisoner 7. Patient is participating in another clinical study that would confound study data

Locations (2)

Erik C. Spayde, MD Inc.

Thousand Oaks, California, United States

Georgia Spine & Neurosurgery Center

Atlanta, Georgia, United States

Outcomes

Primary Outcomes

Rate of Complications

Rate of complications attributable to use of the Modulus XLIF interbody implant

Time frame: At least 12 months

Proportion of subjects with apparent radiographic fusion at 12 months or greater postoperative

Proportion of subjects with fusion at 12 months or greater

Time frame: At least 12 months

Secondary Outcomes

Improvement in neurologic status

Proportion of subjects with neurological improvement as compared to baseline

Time frame: At least 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.